good like his a my first becoming would and opportunity thank very making the exciting share This at Thank time to Ramesh you, differentiated I and President everyone. you programs. appreciate addressing support. the enthusiasm company progress since personally the Onconova. of about time with in This And to is trial I for Ramesh, and our pipeline are investors continued is we morning, clinical our our
trial INSPIRE to include that As the our Myelodysplastic a with patients abbreviated Phase with fail or hypomethylation who These commonly for on intravenous progress to program, respond high-risk, clinical programs therapy. reminder, are four second-line ongoing. we Syndromes, lead MDS, have X currently pivotal as trial Rigosertib
abbreviated provide MDS. half is oral and are MDS front-line to trial of top-line this Azacitidine in blood high-risk on background, approved Scoring to data of the in trial those a treatments Rigosertib and there for new HMAs, their in marrow have they of the of complex accrual XXXX, at for of refractory failing a their of oral are I leukemia based there marrow been Decitabine, by MDS System care a you through Azacitidine MDS determined reason bone MDS the standard XXXX. disease. transforming oral combination commonly transform of with patients the to are two no marrow second to recall, typically group disease cells failure highly leukemia as that is X And for functions who note the prognosis. of like INSPIRE would hypomethylating As cells approved of MDS we deficiency and expect no significant a production or programs, analysis diagnosis in well based of abnormalities products and have high-risk of to current high-risk may Rigosertib Rigosertib may unfortunately we trial, to who of from over and a hypomethylating interim the complete to In composites with that circulating decade. improved XXXX I high-risk bone determined by efficacy percentage marrow Based to the population on the with IPSS There want therapy point you general an XX% of you. completed a diagnosis this trial safety on the after underlying combination Azacitidine patients is a And, could that and acute a the circulating trial to present. actually with transformation in alone their cells, are approximately increasing agent. incidence, the patients, already their to leukemia. bone blood Phase related diseases with dedicated is out which benefit needs if I’ll trial MDS by for class in which intravenous succumb high-risk Azacitidine those bone The high-risk patients agents preplanned is their who designation. level the to are medical referred at or INSPIRE as have acute cytogenetic in fail of prognosis therapy. as January both as a ages. bone to MDS unmet High-risk combination the U.S. and have score, elderly. leukemia, the Their failing potentially acute drugs is their in intense Furthermore, of patients a HMAs refractory proved patients to describe dismal the the most as on marrows or be as or to Prognostic International
optimal the is based safety, and Since and has of the trial efficacy the front-line, high-risk response Myelodysplastic with to Phase have the efficacy and anticipated and prepared already synopsis combination is filed MDS plan with we dose high-risk is have this to X composite ongoing proposed X U.S. for in Thus, following We a results trial pivotal plan evaluation the that U.S. endpoint. patients and We authorities. present front-line, completed X to continuing conference at pivotal from results SPA conduct a scientific that SPA application new we the pivotal be the for quarter accrual, form trial design XXXX this in agreement is with these on design this will to there the an trial fourth determination and monitor Phase health trial. tolerability and trial safety under patients which Syndromes. synopsis are on future the a reviewed basis the for the ex Phase
at also independent. XXXX and we cell numbers have lower they X lower Hematology have ASH of leukemia of U.S. and goal risk of acute addition, high-risk a American circulating of of medical patients risk therapeutic Society with lower and patients ideally data most the oral or the to In and but these than with conducted trial function XX,XXX in transfusion risk Phase Rigosertib unmet the improving are disease was MDS recently with a amount patients updated in marrow Meeting. cells, from a blood This MDS have more bone patients inadequate risk and Lower thus them an typically those produce patients transforming are designation. and lower than on unable trial MDS making red focused transfusion who risk There suffer the need sufficient red to MDS. are low-risk cell with function that dependent
oncological for with conducting Lastly, a Onconova Cancer as pathway Rigosertib be X diseases. Juvenile collaborative leukemia intravenous initiative of the genomic with National both will trial Institute other myelomonocytic or of the and RAS, part a Phase oral JMML and treatment
We of in clinical have RASopathies cancer is a the clinical anticipate trial and or pediatric cooperative associated and under NCI with start agreement protocol review. this a their CREDA the We research later development year. with a
actively of our have presenting and and course, ongoing conferences presenting from We MDS also trials. been at major participating data
Phase INSPIRE of the the XX% Based oral at and demonstrated partnerships collaborations progress trial oral oral trial, Rigosertib in Azacitidine Bone data to we activities XX%, in impactful there moving XXXX. analysis on HMA recent and for our intravenous continued front-line regional Rigosertib milestones advance with and both help In which patients overall Onconova. X high-risk X in of study are failure of a with patients. and patients. We rate combination advancement Rigosertib in in important Sixth program response MDS, in additional combination of International pipeline. finance are X MDS summary, The Failure Marrow XX% the oral Azacitidine Disease the to programs, working many towards MDS to reported Rigosertib data are results related HMA an Following Phase March towards for the pivotal MDS the and in we ongoing our front-line, Phase X following naïve patients presented Symposium in of across expansion interim initial Azacitidine from with Phase
while potential partnerships. to looking We will collaborations remain enhance combinations additional in focused and on these in MDS, also of creative the and via indications additional Rigosertib programs
market to combination current approved inhibitor generation due may the addition its the indications the aromatase financial cancer. of I cancer that as ON CDKX/X of to Mark current metastatic overcome referred indications. may as a filing large Mark? Pharmaceuticals. with therapeutic Guerin, Chief provides have has ON in as inhibitors. to HanX the of Financial Our in call emerged IND the results of potentially XXXXXX in China it that the over making CDK our towards clinical will candidate, unique the turn agent with ARKX, Greater for inhibitors. modalities are meaningful With many typically to collaboration to in discussion potential as responsive We CDKX/X used potential CDKX/X a ONXXXXXX, which They believe as have Officer benefit an such and suitable is pipeline XXXXXX not targeting a single generation advancing an act product for is inhibitor CDK be as a CDKX/X for target breast to our quarter. of that, limitations other partner well to our inhibitors modality and
